Research in The Lancet once again underscores the effectiveness of chemotherapy for hormone-receptor-negative breast cancer. It also shows that tamoxifen has little effect on recurrence or death for hormone negative patients. has a good overview of the research, which uses data from the <a href="
“> Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).

The study looked at chemo from the 1970s and 1980s, which has been shown to be less effective than newer regimens.

Leave a Reply

%d bloggers like this: